{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:24:30Z","timestamp":1773246270852,"version":"3.50.1"},"reference-count":154,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1053\/beem.2002.0231","type":"journal-article","created":{"date-parts":[[2002,12,11]],"date-time":"2002-12-11T01:48:30Z","timestamp":1039571310000},"page":"717-742","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacotherapy of obesity"],"prefix":"10.1053","volume":"16","author":[{"given":"N.","family":"Finer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/beem.2002.0231_RF1","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/sj.ijo.0801791","article-title":"Reply: Is obesity a disease?","volume":"25","author":"Kopelman","year":"2001","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1053\/beem.2002.0231_RF2","unstructured":"Joint Formulary Committee. British National Formulary, 1994"},{"key":"10.1053\/beem.2002.0231_RF3","unstructured":"Joint Formulary Committee. British National Formulary, 2002"},{"key":"10.1053\/beem.2002.0231_RF4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/j.1550-8528.1995.tb00178.x","volume":"3","year":"1995","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF5","first-page":"189","article-title":"ASO consensus statement on obesity","volume":"18","author":"Kopelman","year":"1994","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF6","unstructured":"Scottish Intercollegiate Guidelines Network"},{"key":"10.1053\/beem.2002.0231_RF7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5180","article-title":"A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity","volume":"5","author":"O'Meara","year":"2001","journal-title":"Health Technology Assessment"},{"key":"10.1053\/beem.2002.0231_RF8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6060","article-title":"The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment","volume":"6","author":"O'Meara","year":"2002","journal-title":"Health Technology Assessment"},{"key":"10.1053\/beem.2002.0231_RF9","unstructured":"Bourne, J"},{"key":"10.1053\/beem.2002.0231_RF10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1056\/NEJM193801202180307","article-title":"Benzedrine sulphate as an aid to the treatment of obesity","volume":"218","author":"Lessof","year":"1938","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF11","first-page":"99","article-title":"Testing drugs for abuse liability and behavioral toxicity: progress report from the laboratories at the Johns Hopkins University School of Medicine","volume":"43","author":"Brady","year":"1983","journal-title":"NIDA Research Monographs"},{"key":"10.1053\/beem.2002.0231_RF12","first-page":"171","article-title":"Clinical aspects of the treatment of obesity by drugs: a review","volume":"3","author":"Munro","year":"1979","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF13","series-title":"Central Mechanisms of Anorectic Drugs","article-title":"A comprehensive review of dieythylpropion hydrochloride","author":"Hoekenga","year":"1978"},{"key":"10.1053\/beem.2002.0231_RF14","series-title":"Central Mechanisms of Anorectic Drugs","article-title":"USA drug abuse warning network","author":"Carabillo","year":"1978"},{"key":"10.1053\/beem.2002.0231_RF15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-12-004702-4.50010-2","article-title":"Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens","volume":"2","author":"Griffiths","year":"1979","journal-title":"Advances in Behavioral Pharmacology"},{"key":"10.1053\/beem.2002.0231_RF16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"British Medical Journal"},{"key":"10.1053\/beem.2002.0231_RF17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archinte.144.6.1143","article-title":"A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination","volume":"144","author":"Weintraub","year":"1984","journal-title":"Archives of Internal Medicine"},{"key":"10.1053\/beem.2002.0231_RF18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/030006057600400504","article-title":"Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity","volume":"4","author":"Enzi","year":"1976","journal-title":"Journal of International Medical Research"},{"key":"10.1053\/beem.2002.0231_RF19","first-page":"271","article-title":"A double-blind trial of Mazindol using a very low calorie formula diet","volume":"1","author":"McLean","year":"1977","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF20","series-title":"Obesity in Perspective","first-page":"75","article-title":"Review of amphetamine-like drugs by the Food and Drug Administration","author":"Scoville","year":"1976"},{"key":"10.1053\/beem.2002.0231_RF21","unstructured":"Information Centre MCa, 2001"},{"key":"10.1053\/beem.2002.0231_RF22","first-page":"93","article-title":"Dexfenfluramine: an overview of its mechanisms of action","volume":"2","author":"Campbell","year":"1991","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"10.1053\/beem.2002.0231_RF23","first-page":"35","article-title":"On the in vivo and in vitro actions of fenfluramine and its derivatives on the cntral monoamine neurons especially 5-hydroxytryptamine and their relation to the anorectic activity of fenfluramine","volume":"51","author":"Fuxe","year":"1975","journal-title":"Postgraduate Medical Journal"},{"key":"10.1053\/beem.2002.0231_RF24","first-page":"206","article-title":"Pharmacological study of dexfenfluramine and its optical isomers","volume":"161","author":"Le Douarec","year":"1966","journal-title":"Archives of Internationales de Pharmacodynamie et de Therape"},{"key":"10.1053\/beem.2002.0231_RF25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00003495-199243050-00007","article-title":"Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity","volume":"43","author":"McTavish","year":"1992","journal-title":"Drugs"},{"key":"10.1053\/beem.2002.0231_RF26","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2165\/00003495-199652050-00007","article-title":"Dexfenfluramine. An updated review of its therapeutic use in the management of obesity","volume":"52","author":"Davis","year":"1996","journal-title":"Drugs"},{"key":"10.1053\/beem.2002.0231_RF27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0140-6736(80)92272-2","article-title":"Controlled trial of behavior therapy, pharmacotherapy, and their combination in the treatment of obesity","volume":"ii","author":"Stunkard","year":"1980","journal-title":"Lancet"},{"key":"10.1053\/beem.2002.0231_RF28","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(89)91499-2","article-title":"International trial of long-term dexfenfluramine in obesity","volume":"ii","author":"Guy-Grand","year":"1989","journal-title":"Lancet"},{"key":"10.1053\/beem.2002.0231_RF29","doi-asserted-by":"crossref","first-page":"195s","DOI":"10.1093\/ajcn\/56.1.195S","article-title":"Drug therapy after very low calorie diets","volume":"56","author":"Finer","year":"1992","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1053\/beem.2002.0231_RF30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00003495-199000393-00007","article-title":"Dexfenfluramine: its place in weight control","volume":"39","author":"Turner","year":"1990","journal-title":"Drugs"},{"key":"10.1053\/beem.2002.0231_RF31","first-page":"P511","article-title":"Review of dexfenfluramine efficacy and tolerability","volume":"18","author":"Sandage","year":"1994","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/hrt.70.6.537","article-title":"Primary pulmonary hypertension and fenfluramine use","volume":"70","author":"Brenot","year":"1993","journal-title":"British Heart Journal"},{"key":"10.1053\/beem.2002.0231_RF33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abbenhaim","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM199608293350910","article-title":"Pharmacotherapy for obesity - do the benefits outweight the risks?","volume":"335","author":"Manson","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF36","first-page":"1061","volume":"46","year":"1997","journal-title":"Morbidity and Mortality Weekly Reports"},{"key":"10.1053\/beem.2002.0231_RF37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM199809103391101","article-title":"The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs","volume":"339","author":"Khan","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF38","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199809103391103","article-title":"An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo","volume":"339","author":"Weissman","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/j.1550-8528.1999.tb00412.x","article-title":"Valvular heart disease in fenfluramine-phentermine-treated patients: a comparison with control patients","volume":"7","author":"Wadden","year":"1999","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF40","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1161\/01.CIR.100.21.2161","article-title":"Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine","volume":"100","author":"Shively","year":"1999","journal-title":"Circulation"},{"key":"10.1053\/beem.2002.0231_RF41","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/01.CIR.101.17.2071","article-title":"Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities","volume":"101","author":"Jollis","year":"2000","journal-title":"Circulation"},{"key":"10.1053\/beem.2002.0231_RF42","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine","volume":"283","author":"Gardin","year":"2000","journal-title":"Journal of the American Medical Association"},{"key":"10.1053\/beem.2002.0231_RF43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6904-2-6","article-title":"Appetite suppressants and valvular heart disease\u2013a systematic review","volume":"2","author":"Loke","year":"2002","journal-title":"BMC Clinical Pharmacology"},{"key":"10.1053\/beem.2002.0231_RF44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00000441-200104000-00008","article-title":"Appetite suppressants and valvular heart disease","volume":"321","author":"Weissman","year":"2001","journal-title":"American Journal of Medical Science"},{"key":"10.1053\/beem.2002.0231_RF45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/1098-2299(200010)51:2<52::AID-DDR2>3.0.CO;2-H","article-title":"Neurochemical mechanisms of phentermine and fenfluramine: therapeutic and adverse effects","volume":"51","author":"Rothman","year":"2000","journal-title":"Drug Development and Research"},{"key":"10.1053\/beem.2002.0231_RF46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ajcn\/54.2.321","article-title":"Fluoxetine's effect on weight loss in obese subjects","volume":"54","author":"Darga","year":"1991","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1053\/beem.2002.0231_RF47","first-page":"185","article-title":"Fluoxetine-induced weight loss in overweight non-depressed humans","volume":"11","author":"Ferguson","year":"1987","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF48","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/j.1550-8528.1993.tb00597.x","article-title":"Fluoxetine: a randomised clinical trial in the maintenance ofweight loss","volume":"1","author":"Goldstein","year":"1993","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF49","first-page":"129","article-title":"Fluoxetine: a randomized clinical trial in the treatment of obesity","volume":"18","author":"Goldstein","year":"1994","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1053\/beem.2002.0231_RF50","first-page":"S67","article-title":"A randomized double-blind clinical trial of fluoxetine in obese diabetics","volume":"16","author":"Gray","year":"1992","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF51","first-page":"635","article-title":"Use of fluoxetine, a selective serotonin uptake inhibitor, in thetreatment of obesity","volume":"13","author":"Levine","year":"1989","journal-title":"International Journal of Obesity: a dose\u2013response study"},{"key":"10.1053\/beem.2002.0231_RF52","first-page":"635","article-title":"Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose\u2013response study (with a Commentary by Michael Weintraub)","volume":"13","author":"Levine","year":"1989","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF53","first-page":"185","article-title":"Use of a serotonin re-uptake inhibitor, fluoxetine, in thetreatment of obesity","volume":"11","author":"Levine","year":"1987","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF54","first-page":"191","article-title":"Safety of fluoxetine in the treatment of obesity","volume":"11","author":"Zerbe","year":"1987","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF55","series-title":"Obesity: Theory and Therapy","first-page":"275","article-title":"The place of appetite-suppressant drugs in the treatment of obesity","author":"Silverstone","year":"1993"},{"key":"10.1053\/beem.2002.0231_RF56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0022-3999(86)90043-7","article-title":"Placebo controlled double-blind trial of fluvoxamine maleate in the obese","volume":"30","author":"Abell","year":"1986","journal-title":"Journal of Psychosomatic Research"},{"key":"10.1053\/beem.2002.0231_RF57","first-page":"301","article-title":"Fluvoxamine: an open pilot study in moderately obese female patients suffering from atypical eating disorders and episodes of bingeing","volume":"17","author":"Gardiner","year":"1993","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF58","first-page":"53","article-title":"The neuropharmacology of obesity","volume":"2","author":"Samanin","year":"1991","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"10.1053\/beem.2002.0231_RF59","doi-asserted-by":"crossref","first-page":"185S","DOI":"10.1093\/ajcn\/55.1.185s","article-title":"Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice","volume":"55","author":"Nielsen","year":"1992","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1053\/beem.2002.0231_RF60","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF03347875","article-title":"Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients","volume":"19","author":"Ricca","year":"1996","journal-title":"Journal of Endocrinology Investigation"},{"key":"10.1053\/beem.2002.0231_RF61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2337\/diacare.1.4.223","article-title":"Use of fructose, sorbitol, or xylitol as a sweetener in diabetes mellitus","volume":"1","author":"Brunzell","year":"1978","journal-title":"Diabetes Care"},{"key":"10.1053\/beem.2002.0231_RF62","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ajcn\/57.2.120","article-title":"Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women","volume":"57","author":"Alger","year":"1993","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1053\/beem.2002.0231_RF63","first-page":"569","article-title":"Invited commentary: phenylpropanolamine and the medical literature: a thorough reading is required","volume":"14","author":"Morgan","year":"1990","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF64","doi-asserted-by":"crossref","first-page":"707","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00016","article-title":"Use and abuse of appetite-suppressant drugs in the treatment of obesity","volume":"119","author":"Bray","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1053\/beem.2002.0231_RF65","series-title":"Phenylpropanolamine: Risks, Benefits and Controversies","first-page":"53","article-title":"Phenylpropanolamine as an anorexiant agent in weight control: a review of published and unpublished studies","author":"Weintraub","year":"1985"},{"key":"10.1053\/beem.2002.0231_RF66","doi-asserted-by":"crossref","first-page":"203S","DOI":"10.1093\/ajcn\/55.1.203s","article-title":"Clinical studies with phenylpropanolamine: a meta-analysis","volume":"55","author":"Greenway","year":"1992","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1053\/beem.2002.0231_RF67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0002-9343(90)90299-S","article-title":"Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports","volume":"89","author":"Lake","year":"1990","journal-title":"American Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF68","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1056\/NEJM200012213432501","article-title":"Phenylpropanolamine and the risk of hemorrhagic stroke","volume":"343","author":"Kernan","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF69","unstructured":"Center for Drug Evaluation and Research"},{"key":"10.1053\/beem.2002.0231_RF70","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/bmj.311.7002.437","article-title":"Obesity in Britain: obesity or sloth?","volume":"311","author":"Prentice","year":"1995","journal-title":"British Medical Journal"},{"key":"10.1053\/beem.2002.0231_RF71","series-title":"The Treatment of Morbid Obesity","first-page":"213","article-title":"Health Consequences of therapeutic weight loss: reducing primary risk factors","author":"Kanders","year":"1992"},{"key":"10.1053\/beem.2002.0231_RF72","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein","year":"1992","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF73","unstructured":"Committee for Proprietary Medicinal Products"},{"key":"10.1053\/beem.2002.0231_RF74","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2125.1988.tb05303.x","article-title":"Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers","volume":"26","author":"King","year":"1988","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1053\/beem.2002.0231_RF75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0091-3057(98)00032-X","article-title":"Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake","volume":"61","author":"Halford","year":"1998","journal-title":"Pharmacology and Biochemical Behavior"},{"key":"10.1053\/beem.2002.0231_RF76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.1550-8528.1998.tb00308.x","article-title":"Sibutramine reduces food intake in non-dieting women with obesity","volume":"6","author":"Rolls","year":"1998","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF77","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0031-9384(99)00176-6","article-title":"Modalities of the food intake-reducing effect of sibutramine in humans","volume":"68","author":"Chapelot","year":"2000","journal-title":"Physiology and Behavior"},{"key":"10.1053\/beem.2002.0231_RF78","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/sj.bjp.0702446","article-title":"Thermogenic effects of sibutramine and its metabolites","volume":"126","author":"Connoley","year":"1999","journal-title":"British Journal of Pharmacology"},{"key":"10.1053\/beem.2002.0231_RF79","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/j.1550-8528.1998.tb00324.x","article-title":"Effects of sibutramine on resting metabolic rate and weight loss in overweight women","volume":"6","author":"Seagle","year":"1998","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF80","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.ijo.0801045","article-title":"The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females","volume":"23","author":"Walsh","year":"1999","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1053\/beem.2002.0231_RF81","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/00003495-199856060-00019","article-title":"Sibutramine. A review of its contribution to the management of obesity","volume":"56","author":"McNeely","year":"1998","journal-title":"Drugs"},{"key":"10.1053\/beem.2002.0231_RF82","unstructured":"National Institute for Clinical Excellence, Guidance on the use of sibutramine for the treatment of obesity in adults, 2001"},{"key":"10.1053\/beem.2002.0231_RF83","first-page":"S183","article-title":"Paradoxical cardiovascular effects of sibutramine","volume":"26","author":"Birkenfield","year":"2002","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF84","unstructured":"Committee for Proprietary Medicinal Products"},{"key":"10.1053\/beem.2002.0231_RF85","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/j.1550-8528.1996.tb00544.x","article-title":"A double-blind randomised placebo-controlled trial of sibutramine","volume":"4","author":"Bray","year":"1996","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF87","first-page":"41","article-title":"Long term weight loss with sibutramine","volume":"19","author":"Jones","year":"1995","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF88","first-page":"2119","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial","volume":"256","author":"James","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/beem.2002.0231_RF89","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"American Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF90","first-page":"41","article-title":"Sibutramine in the treatment of overweight non-insulin dependent diabetics","volume":"19","author":"Griffiths","year":"1995","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF91","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus","volume":"2","author":"Fujioka","year":"2000","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1053\/beem.2002.0231_RF92","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.ijo.0801935","article-title":"The importance of obesity in diabetes and its treatment with sibutramine","volume":"25","author":"Van Gaal","year":"2001","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1053\/beem.2002.0231_RF93","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2337\/diacare.10.5.563","article-title":"Type II diabetic subjects lose less weight than their overweight nondiabetic spouses","volume":"10","author":"Wing","year":"1987","journal-title":"Diabetes Care"},{"key":"10.1053\/beem.2002.0231_RF94","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/sj.ijo.0801932","article-title":"Sibutramine in clinical practice","volume":"25","author":"Finer","year":"2001","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1053\/beem.2002.0231_RF95","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.jhh.1001298","article-title":"Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors","volume":"16","author":"McMahon","year":"2002","journal-title":"Journal of Human Hypertension"},{"key":"10.1053\/beem.2002.0231_RF96","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000047310","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients","volume":"94","author":"Hazenberg","year":"2000","journal-title":"Cardiology"},{"key":"10.1053\/beem.2002.0231_RF97","doi-asserted-by":"crossref","first-page":"309S","DOI":"10.1093\/ajcn\/55.1.309s","article-title":"Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro18-0647 (tetrahydrolipstatin)","volume":"55","author":"Hauptman","year":"1992","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1053\/beem.2002.0231_RF98","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/clpt.1994.104","article-title":"Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers","volume":"56","author":"Zhi","year":"1994","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1053\/beem.2002.0231_RF99","first-page":"241","article-title":"Lipase inhibition: a novel concept in the treatment of obesity","volume":"17","author":"Drent","year":"1993","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2125.1993.tb04228.x","article-title":"Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake","volume":"36","author":"Hartmann","year":"1993","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1053\/beem.2002.0231_RF101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/00912709922007543","article-title":"Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients","volume":"39","author":"Zhi","year":"1999","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1053\/beem.2002.0231_RF102","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/j.1552-4604.1995.tb04034.x","article-title":"Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers","volume":"35","author":"Zhi","year":"1995","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1053\/beem.2002.0231_RF103","first-page":"276","article-title":"Orlistat: a new agent for the treatment of obesity","volume":"6","author":"Mulcahy","year":"1999","journal-title":"British Journal of Cardiology"},{"key":"10.1053\/beem.2002.0231_RF104","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2165\/00003495-199856020-00007","article-title":"Orlistat","volume":"56","author":"McNeely","year":"1998","journal-title":"Drugs"},{"key":"10.1053\/beem.2002.0231_RF105","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-199958040-00015","article-title":"Orlistat: a review of its use in the management of obesity","volume":"58","author":"Hvizdos","year":"1999","journal-title":"Drugs"},{"key":"10.1053\/beem.2002.0231_RF106","unstructured":"National Institute for Clinical Excellence"},{"key":"10.1053\/beem.2002.0231_RF107","unstructured":"O'Meara, S, Riemsma, R, Shirran, L, A systematic review of the clinical effectiveness and cost effectiveness of orlistat in the management of obesity"},{"key":"10.1053\/beem.2002.0231_RF108","first-page":"221","article-title":"Orlistat (Ro18-0647), a lipase inhibitor, in the treatment of obesity: a multiple dose study","volume":"19","author":"Drent","year":"1995","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF109","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"International Journal of Obesity and Related Metabolic Disorder"},{"key":"10.1053\/beem.2002.0231_RF110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"Journal of the American Medical Association"},{"key":"10.1053\/beem.2002.0231_RF111","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","article-title":"Orlistat in the long-term treatment of obesity in primary care settings","volume":"9","author":"Hauptman","year":"2000","journal-title":"Archives of Family Medicine"},{"key":"10.1053\/beem.2002.0231_RF112","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity","volume":"8","author":"Rossner","year":"2000","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF113","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/beem.2002.0231_RF114","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2165\/00003495-200161140-00011","article-title":"Orlistat: in the prevention and treatment of type 2 diabetes mellitus","volume":"61","author":"Keating","year":"2001","journal-title":"Drugs"},{"key":"10.1053\/beem.2002.0231_RF115","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","article-title":"Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults","volume":"160","author":"Heymsfield","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1053\/beem.2002.0231_RF116","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF117","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF118","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/oby.2001.79","article-title":"Orlistat inhibits dietary cholesterol absorption","volume":"9","author":"Mittendorfer","year":"2001","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF119","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00004872-199816121-00024","article-title":"Treatment with orlistat reduces cardiovascular risk in obese patients","volume":"16","author":"Zavoral","year":"1998","journal-title":"Journal of Hypertension"},{"key":"10.1053\/beem.2002.0231_RF120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study","volume":"248","author":"Lindgarde","year":"2000","journal-title":"Journal of Internal Medicine"},{"key":"10.1053\/beem.2002.0231_RF121","doi-asserted-by":"crossref","first-page":"497S","DOI":"10.1002\/j.1550-8528.1995.tb00218.x","article-title":"Combined treatment of obesity","volume":"3","author":"Atkinson","year":"1995","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF122","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1992.68","article-title":"Long-term weight control: the National Heart, Lung and Blood Institute funded multimodal intervention study","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clinical Phamacology and Therapeutics"},{"key":"10.1053\/beem.2002.0231_RF123","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/oby.2000.53","article-title":"Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial","volume":"8","author":"Wadden","year":"2000","journal-title":"Obesity Research"},{"key":"10.1053\/beem.2002.0231_RF124","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ajcn\/49.5.1115","article-title":"Exercise as an adjunct to weight loss and maintenance in moderately obese individuals","volume":"49","author":"Pavlou","year":"1989","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1053\/beem.2002.0231_RF125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1385\/ENDO:13:2:207","article-title":"Thermogenic drugs as a strategy for treatment of obesity","volume":"13","author":"Astrup","year":"2000","journal-title":"Endocrine"},{"key":"10.1053\/beem.2002.0231_RF126","series-title":"Obesity,","first-page":"762","article-title":"Thermogenic drugs","author":"Cawthorne","year":"1992"},{"key":"10.1053\/beem.2002.0231_RF127","first-page":"681","article-title":"Long term weight regulation in treated hyperthyroid and hypothyroid patients","volume":"30","author":"Hoogwerf","year":"1984","journal-title":"American Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF128","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0002-9343(02)01022-7","article-title":"A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism","volume":"112(5)","author":"Kong","year":"2002","journal-title":"American Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF129","first-page":"P106","article-title":"Is hypothyroidism a cause of obesity?","volume":"151","author":"Lessan","year":"1996","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.2002.0231_RF130","first-page":"183","article-title":"Ephedrine as an anorectic: the story of the \u2018Elsinore pill\u2019","volume":"5","author":"Malchow-Moller","year":"1981","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF131","first-page":"S29","article-title":"Sympathoadrenal activity and obesity: physiological rationale for the use of adrenergic thermogenic drugs","volume":"17","author":"Landsberg","year":"1993","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF132","first-page":"269","article-title":"The effect and safety of an ephedrine\/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial","volume":"16","author":"Astrup","year":"1992","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF133","first-page":"99","article-title":"Comparison of an ephedrine\/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice","volume":"18","author":"Breum","year":"1994","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF134","first-page":"S73","article-title":"Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity","volume":"17","author":"Daly","year":"1993","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF135","first-page":"269","article-title":"The effect and safety of an ephedrine\/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A doubt blind trial","volume":"16(4)","author":"Astrup","year":"1992","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1053\/beem.2002.0231_RF136","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ajcn\/38.4.549","article-title":"Thermogenic and antiobesity activity of a novel \u03b2-adrenorecptor agonist (BRL 26830A) in mice and rats","volume":"38","author":"Arch","year":"1983","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1053\/beem.2002.0231_RF137","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199508103330612","article-title":"The \u03b23-adrenergic receptor - a cause and cure of obesity?","volume":"333","author":"Arner","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF138","first-page":"119","article-title":"The effects of a new \u03b2-adrenoreceptor agonist BRL 26830A in refractory obesity","volume":"12","author":"Chapman","year":"1988","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF139","first-page":"473","article-title":"Thermogenic effect of the new \u03b2-adrenoreceptor agonist RO 16-8714 in healthy male volunteers","volume":"11","author":"Henny","year":"1987","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF140","first-page":"757","article-title":"Effects of BRL 35135, a \u03b2-adrenoreceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects","volume":"13","author":"Mitchell","year":"1989","journal-title":"International Journal of Obesity"},{"key":"10.1053\/beem.2002.0231_RF141","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/1098-2299(200010)51:2<80::AID-DDR4>3.0.CO;2-E","article-title":"Development of \u03b2-3 adrenoreceptor agonists as antiobesity and antidiabetes drugs in humans: current status and future prospects","volume":"51","author":"Weyer","year":"2000","journal-title":"Drug Development Research"},{"key":"10.1053\/beem.2002.0231_RF142","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"key":"10.1053\/beem.2002.0231_RF143","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM199602013340511","article-title":"Obesity, leptin, and the brain","volume":"334","author":"Rohner-Jeanrenaud","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF144","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJM199909163411204","article-title":"Effects of recombinant leptin therapy in a child with congenital leptin deficiency [see comments]","volume":"341","author":"Farooqi","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF145","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJM199602013340503","article-title":"Serum immunoreactive-leptin concentrations in normal-weight and obese humans","volume":"334","author":"Considine","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.2002.0231_RF146","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/1098-2299(200010)51:2<66::AID-DDR3>3.0.CO;2-1","article-title":"Leptin and the treatment of obesity","volume":"51","author":"Walder","year":"2002","journal-title":"Drug Development and Research"},{"key":"10.1053\/beem.2002.0231_RF147","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"Journal of the American Medical Association"},{"key":"10.1053\/beem.2002.0231_RF148","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/1098-2299(200010)51:2<94::AID-DDR5>3.0.CO;2-Z","article-title":"NPY-ergic agents for the treatment of obesity","volume":"51","author":"Zimanyi","year":"2000","journal-title":"Drug Development and Research"},{"key":"10.1053\/beem.2002.0231_RF149","doi-asserted-by":"crossref","unstructured":"Smith, G, P, Gibbs, F, P, Satiating effects of cholecystokinin, Annals of the New York Academy of Sciences, 1994, 713, 236, 241","DOI":"10.1111\/j.1749-6632.1994.tb44071.x"},{"key":"10.1053\/beem.2002.0231_RF150","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(96)90825-9","article-title":"Fighting obesity the Franco-British way","volume":"347(9017)","author":"Jack","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/beem.2002.0231_RF151","series-title":"Regulation of Body Weight: Biological and Behavioural Mechanisms","first-page":"179","article-title":"Peptides in the regulation of energy metabolism and body weight","author":"Levine","year":"1996"},{"key":"10.1053\/beem.2002.0231_RF152","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nature00887","article-title":"Gut hormone PYY(3-36) physiologically inhibits food intake","volume":"418","author":"Batterham","year":"2002","journal-title":"Nature"},{"key":"10.1053\/beem.2002.0231_RF153","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1053\/beem.2002.0231_RF154","unstructured":"Food and Drug Administration, Guidance for the clinical evaluation of weight control drugs, 1997"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X02902319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X02902319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T04:55:52Z","timestamp":1554180952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X02902319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":154,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["S1521690X02902319"],"URL":"https:\/\/doi.org\/10.1053\/beem.2002.0231","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}